Form 8-K - Current report:
SEC Accession No. 0001628280-25-029639
Filing Date
2025-06-05
Accepted
2025-06-05 16:10:21
Documents
15
Period of Report
2025-06-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20250603.htm   iXBRL 8-K 36407
2 EX-1.1 ex-11_salesagreementjune20.htm EX-1.1 284572
3 EX-5.1 ex-51legalopinionconsentat.htm EX-5.1 7317
  Complete submission text file 0001628280-25-029639.txt   527831

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20250603.xsd EX-101.SCH 2104
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20250603_def.xml EX-101.DEF 14550
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20250603_lab.xml EX-101.LAB 24544
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20250603_pre.xml EX-101.PRE 15065
17 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20250603_htm.xml XML 2629
Mailing Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087
Business Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 251027194
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)